Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis.

ABSTRACT: Approximately 30% of patients treated with ipilimumab will develop gastrointestinal toxicity. The immunological drivers that underpin the clinical observations in human tissues are poorly understood. We report here on the immune consequences of ipilimumab treatment in the colorectal mucosa of patients with treatment-related colitis. Using immunohistochemistry, we evaluated the immune infiltrate by CD8⁺, FoxP3, and granzyme B (GzmB) in colonic biopsies from 20 patients with ipilimumab-related colitis. We assessed 10 cases with normal colon biopsies for comparison. In eight cases (four on steroids only, four on steroids and infliximab), we evaluated two sequential biopsies. We observed that CD8⁺, FoxP3⁺, and GzmB T cell counts were significantly higher in pat

SUBMITTER: Arriola E 

PROVIDER: S-EPMC5048766 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature